ATVB distinguished scientist award: How Costimulatory and Coinhibitory pathways shape atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 5, 2017, Pages 764-777

  Ley, Klaus ^a   Gerdes, Norbert ^b,c   Winkels, Holger ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

antigen presenting cells; atherosclerosis; B lymphocytes; immunoglobulins; receptors, tumor necrosis factor

Indexed keywords

B7 ANTIGEN; CD137 ANTIGEN; CD137 LIGAND; CD27 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CD30 LIGAND; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD70 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GLUCOCORTICOIDINDUCED TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEIN; HERPESVIRUS ENTRY MEDIATOR; MONOCLONAL ANTIBODY; OX40 LIGAND; OX40 PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN PRESENTING CELL; ATHEROSCLEROSIS; AWARDS AND PRIZES; CANCER THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CD4+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTERY; B LYMPHOCYTE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; ANTIGENS, CD28; ARTERIES; ATHEROSCLEROSIS; B-LYMPHOCYTES; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 85016630909     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.117.308611     Document Type: Review

References (213)

1. Lozano R, Naghavi M, Foreman K, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012 380 2095 2128. doi: 10.1016/S0140-6736(12)61728-0.
2. Kalanuria AA, Nyquist P, Ling G, The prevention and regression of atherosclerotic plaques: emerging treatments. Vasc Health Risk Manag 2012 8 549 561. doi: 10.2147/VHRM.S27764.
3. Lusis AJ, Atherosclerosis. Nature 2000 407 233 241. doi: 10.1038/35025203.
4. Witztum JL, Lichtman AH, The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol 2014 9 73 102. doi: 10.1146/annurev-pathol-020712-163936.
5. Weber C, Noels H, Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011 17 1410 1422. doi: 10.1038/nm.2538.
6. Galkina E, Ley K, Immune and inflammatory mechanisms of atherosclerosis (∗). Annu Rev Immunol 2009 27 165 197. doi: 10.1146/annurev.immunol.021908.132620.
7. Wang XQ, Nigro P, World C, Fujiwara K, Yan C, Berk BC, Thioredoxin interacting protein promotes endothelial cell inflammation in response to disturbed flow by increasing leukocyte adhesion and repressing Kruppel-like factor 2. Circ Res 2012 110 560 568. doi: 10.1161/CIRCRESAHA.111.256362.
8. Steffensen LB, Mortensen MB, Kjolby M, Hagensen MK, Oxvig C, Bentzon JF, Disturbed laminar blood flow vastly augments lipoprotein retention in the artery wall: a key mechanism distinguishing susceptible from resistant sites. Arterioscler Thromb Vasc Biol 2015 35 1928 1935. doi: 10.1161/ATVBAHA.115.305874.
9. Weber C, Zernecke A, Libby P, The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008 8 802 815. doi: 10.1038/nri2415.
10. Robbins CS, Hilgendorf I, Weber GF, Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 2013 19 1166 1172. doi: 10.1038/nm.3258.
11. van Gils JM, Derby MC, Fernandes LR, The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol 2012 13 136 143. doi: 10.1038/ni.2205.
12. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL, Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A 1989 86 1372 1376
13. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL, Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994 14 32 40
14. Millonig G, Niederegger H, Rabl W, Hochleitner BW, Hoefer D, Romani N, Wick G, Network of vascular-associated dendritic cells in intima of healthy young individuals. Arterioscler Thromb Vasc Biol 2001 21 503 508
15. Moore KJ, Tabas I, Macrophages in the pathogenesis of atherosclerosis. Cell 2011 145 341 355. doi: 10.1016/j.cell.2011.04.005.
16. Paulson KE, Zhu SN, Chen M, Nurmohamed S, Jongstra-Bilen J, Cybulsky MI, Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ Res 2010 106 383 390. doi: 10.1161/CIRCRESAHA.109.210781.
17. Llodrá J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ, Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A 2004 101 11779 11784. doi: 10.1073/pnas.0403259101.
18. Jonasson L, Holm J, Skalli O, Gabbiani G, Hansson GK, Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985 76 125 131. doi: 10.1172/JCI111934.
19. Koltsova EK, Garcia Z, Chodaczek G, Landau M, McArdle S, Scott SR, von Vietinghoff S, Galkina E, Miller YI, Acton ST, Ley K, Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest 2012 122 3114 3126. doi: 10.1172/JCI61758.
20. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K, Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med 2006 203 1273 1282. doi: 10.1084/jem.20052205.
21. Mohanta SK, Yin C, Peng L, Srikakulapu P, Bontha V, Hu D, Weih F, Weber C, Gerdes N, Habenicht AJ, Artery tertiary lymphoid organs contribute to innate and adaptive immune responses in advanced mouse atherosclerosis. Circ Res 2014 114 1772 1787. doi: 10.1161/CIRCRESAHA.114.301137.
22. Okada T, Miller MJ, Parker I, Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 2005 3 e150
23. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK, Visualization of specific B and T lymphocyte interactions in the lymph node. Science 1998 281 96 99
24. Batista FD, Harwood NE, The who, how and where of antigen presentation to B cells. Nat Rev Immunol 2009 9 15 27. doi: 10.1038/nri2454.
25. Crawford A, Macleod M, Schumacher T, Corlett L, Gray D, Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 2006 176 3498 3506
26. Giles JR, Kashgarian M, Koni PA, Shlomchik MJ, B Cell-specific MHC class II deletion reveals multiple nonredundant roles for B cell antigen presentation in murine lupus. J Immunol 2015 195 2571 2579. doi: 10.4049/jimmunol.1500792.
27. Molnarfi N, Schulze-Topphoff U, Weber MS, MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 2013 210 2921 2937. doi: 10.1084/jem.20130699.
28. Wick G, Jakic B, Buszko M, Wick MC, Grundtman C, The role of heat shock proteins in atherosclerosis. Nat Rev Cardiol 2014 11 516 529. doi: 10.1038/nrcardio.2014.91.
29. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, Boullier A, Gonen A, Diehl CJ, Que X, Montano E, Shaw PX, Tsimikas S, Binder CJ, Witztum JL, Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011 108 235 248. doi: 10.1161/CIRCRESAHA.110.223875.
30. Paulsson G, Zhou X, Törnquist E, Hansson GK, Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2000 20 10 17
31. Tse K, Gonen A, Sidney J, Ouyang H, Witztum JL, Sette A, Tse H, Ley K, Atheroprotective vaccination with MHC-II restricted peptides from ApoB-100. Front Immunol 2013 4 493. doi: 10.3389/fimmu.2013.00493.
32. Kimura T, Tse K, McArdle S, Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells. Am J Physiol Heart Circ Physiol 2017;4:H781-H790. doi: 10.1152/ajpheart.00798.2016.
33. Fredrikson GN, Söderberg I, Lindholm M, Dimayuga P, Chyu KY, Shah PK, Nilsson J, Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003 23 879 884. doi: 10.1161/01.ATV.0000067937.93716.DB.
34. Hansson GK, Holm J, Jonasson L, Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989 135 169 175
35. van Dijk RA, Duinisveld AJ, Schaapherder AF, A change in inflammatory footprint precedes plaque instability: a systematic evaluation of cellular aspects of the adaptive immune response in human atherosclerosis. J Am Heart Assoc 2015 4
36. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH, T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A 2005 102 1596 1601. doi: 10.1073/pnas.0409015102.
37. Gupta S, Pablo AM, Jiang Xc, Wang N, Tall AR, Schindler C, IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997 99 2752 2761. doi: 10.1172/JCI119465.
38. Li J, McArdle S, Gholami A, Kimura T, Wolf D, Gerhardt T, Miller J, Weber C, Ley K, CCR5+T-bet+FoxP3+ Effector CD4 T Cells Drive Atherosclerosis. Circ Res 2016 118 1540 1552. doi: 10.1161/CIRCRESAHA.116.308648.
39. Butcher MJ, Filipowicz AR, Waseem TC, McGary CM, Crow KJ, Magilnick N, Boldin M, Lundberg PS, Galkina EV, Atherosclerosis-driven Treg plasticity results in formation of a dysfunctional subset of plastic IFNγ+ Th1/Tregs. Circ Res 2016 119 1190 1203. doi: 10.1161/CIRCRESAHA.116.309764.
40. King VL, Szilvassy SJ, Daugherty A, Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. Arterioscler Thromb Vasc Biol 2002 22 456 461
41. Cardilo-Reis L, Gruber S, Schreier SM, Drechsler M, Papac-Milicevic N, Weber C, Wagner O, Stangl H, Soehnlein O, Binder CJ, Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med 2012 4 1072 1086. doi: 10.1002/emmm.201201374.
42. Davenport P, Tipping PG, The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003 163 1117 1125. doi: 10.1016/S0002-9440(10)63471-2.
43. Erbel C, Chen L, Bea F, Wangler S, Celik S, Lasitschka F, Wang Y, Böckler D, Katus HA, Dengler TJ, Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol 2009 183 8167 8175. doi: 10.4049/jimmunol.0901126.
44. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K, Galkina E, Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010 121 1746 1755. doi: 10.1161/CIRCULATIONAHA.109.924886.
45. Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, Esposito B, Perez N, Yasukawa H, Van Snick J, Yoshimura A, Tedgui A, Mallat Z, Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009 206 2067 2077. doi: 10.1084/jem.20090545.
46. Gisterå A, Robertson AK, Andersson J, Ketelhuth DF, Ovchinnikova O, Nilsson SK, Lundberg AM, Li MO, Flavell RA, Hansson GK, Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med 2013 5 196ra100. doi: 10.1126/scitranslmed.3006133.
47. Klein L, Jovanovic K, Regulatory T cell lineage commitment in the thymus. Semin Immunol 2011 23 401 409. doi: 10.1016/j.smim.2011.06.003.
48. Klein L, Kyewski B, Allen PM, Hogquist KA, Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). Nat Rev Immunol 2014 14 377 391. doi: 10.1038/nri3667.
49. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM, Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003 198 1875 1886. doi: 10.1084/jem.20030152.
50. Spitz C, Winkels H, Bürger C, Weber C, Lutgens E, Hansson GK, Gerdes N, Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential. Cell Mol Life Sci 2016 73 901 922. doi: 10.1007/s00018-015-2080-2.
51. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A, Protective role of interleukin-10 in atherosclerosis. Circ Res 1999 85 e17 e24
52. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK, Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 2003 112 1342 1350. doi: 10.1172/JCI18607.
53. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z, Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006 12 178 180. doi: 10.1038/nm1343.
54. Klingenberg R, Gerdes N, Badeau RM, Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest 2013 123 1323 1334. doi: 10.1172/JCI63891.
55. Maganto-García E, Tarrio ML, Grabie N, Bu DX, Lichtman AH, Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation 2011 124 185 195. doi: 10.1161/CIRCULATIONAHA.110.006411.
56. Potekhina AV, Pylaeva E, Provatorov S, Ruleva N, Masenko V, Noeva E, Krasnikova T, Arefieva T, Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis. Atherosclerosis 2015 238 17 21. doi: 10.1016/j.atherosclerosis.2014.10.088.
57. Ait-Oufella H, Tedgui A, Regulatory T-cell plasticity: another layer of complexity in atherosclerosis. Circ Res 2016 118 1461 1463. doi: 10.1161/CIRCRESAHA.116.308805.
58. Kyaw T, Toh BH, Bobik A, Foxp3+CD4+ regulatory T-cell subtypes and atherosclerosis. Circ Res 2016 119 1151 1153. doi: 10.1161/CIRCRESAHA.116.309999.
59. Viola A, Lanzavecchia A, T cell activation determined by T cell receptor number and tunable thresholds. Science 1996 273 104 106
60. Mestas J, Hughes CC, Of mice and not men: differences between mouse and human immunology. J Immunol 2004 172 2731 2738
61. Ville S, Poirier N, Blancho G, Vanhove B, Co-stimulatory blockade of the CD28/CD80-86/CTLA-4 balance in transplantation: impact on memory T cells? Front Immunol 2015 6 411. doi: 10.3389/fimmu.2015.00411.
62. Lenschow DJ, Walunas TL, Bluestone JA, CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996 14 233 258. doi: 10.1146/annurev.immunol.14.1.233.
63. Wells AD, Walsh MC, Bluestone JA, Turka LA, Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 2001 108 895 903. doi: 10.1172/JCI13220.
64. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006 355 1018 1028. doi: 10.1056/NEJMoa063842.
65. Hünig T, Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 2007 95 111 148. doi: 10.1016/S0065-2776(07)95004-X.
66. Dopheide JF, Sester U, Schlitt A, Horstick G, Rupprecht HJ, Münzel T, Blankenberg S, Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro. Coron Artery Dis 2007 18 523 531. doi: 10.1097/MCA.0b013e3282eff1ad.
67. de Boer OJ, Hirsch F, van der Wal AC, van der Loos CM, Das PK, Becker AE, Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. Atherosclerosis 1997 133 227 234
68. Müller A, Mu L, Meletta R, Beck K, Rancic Z, Drandarov K, Kaufmann PA, Ametamey SM, Schibli R, Borel N, Krämer SD, Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules. Int J Cardiol 2014 174 503 515. doi: 10.1016/j.ijcard.2014.04.071.
69. Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman AH, B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2004 109 2009 2015. doi: 10.1161/01.CIR.0000127121.16815.F1.
70. Yilmaz A, Lochno M, Traeg F, Cicha I, Reiss C, Stumpf C, Raaz D, Anger T, Amann K, Probst T, Ludwig J, Daniel WG, Garlichs CD, Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004 176 101 110. doi: 10.1016/j.atherosclerosis.2004.04.027.
71. Rohm I, Atiskova Y, Drobnik S, Fritzenwanger M, Kretzschmar D, Pistulli R, Zanow J, Krönert T, Mall G, Figulla HR, Yilmaz A, Decreased regulatory T cells in vulnerable atherosclerotic lesions: imbalance between pro- and anti-inflammatory cells in atherosclerosis. Mediators Inflamm 2015 2015 364710. doi: 10.1155/2015/364710.
72. Krzyzak L, Seitz C, Urbat A, Hutzler S, Ostalecki C, Gläsner J, Hiergeist A, Gessner A, Winkler TH, Steinkasserer A, Nitschke L, CD83 modulates B cell activation and germinal center responses. J Immunol 2016 196 3581 3594. doi: 10.4049/jimmunol.1502163.
73. Fujimoto Y, Tu L, Miller AS, Bock C, Fujimoto M, Doyle C, Steeber DA, Tedder TF, CD83 expression influences CD4+ T cell development in the thymus. Cell 2002 108 755 767
74. von Rohrscheidt J, Petrozziello E, Nedjic J, Federle C, Krzyzak L, Ploegh HL, Ishido S, Steinkasserer A, Klein L, Thymic CD4 T cell selection requires attenuation of March8-mediated MHCII turnover in cortical epithelial cells through CD83. J Exp Med 2016 213 1685 1694. doi: 10.1084/jem.20160316.
75. Kretschmer B, Lüthje K, Ehrlich S, Osterloh A, Piedavent M, Fleischer B, Breloer M, CD83 on murine APC does not function as a costimulatory receptor for T cells. Immunol Lett 2008 120 87 95. doi: 10.1016/j.imlet.2008.07.004.
76. Chen L, Zhu Y, Zhang G, Gao C, Zhong W, Zhang X, CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2. Proc Natl Acad Sci U S A 2011 108 18778 18783. doi: 10.1073/pnas.1018994108.
77. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ, Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996 14 591 617. doi: 10.1146/annurev.immunol.14.1.591.
78. Jansen MF, Hollander MR, van Royen N, Horrevoets AJ, Lutgens E, CD40 in coronary artery disease: a matter of macrophages? Basic Res Cardiol 2016 111 38. doi: 10.1007/s00395-016-0554-5.
79. Chatzigeorgiou A, Lyberi M, Chatzilymperis G, Nezos A, Kamper E, CD40/CD40L signaling and its implication in health and disease. Biofactors 2009 35 474 483. doi: 10.1002/biof.62.
80. Fuleihan R, Ramesh N, Geha RS, Role of CD40-CD40-ligand interaction in Ig-isotype switching. Curr Opin Immunol 1993 5 963 967
81. Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H, The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994 1 167 178
82. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J, Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994 180 1263 1272
83. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G, Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996 184 747 752
84. Suttles J, Stout RD, Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol 2009 21 257 264. doi: 10.1016/j.smim.2009.05.011.
85. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D, Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995 155 4917 4925
86. Ferrari-Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM, Human lung tissue macrophages, but not alveolar macrophages, express matrix metalloproteinases after direct contact with activated T lymphocytes. Am J Respir Cell Mol Biol 2001 24 442 451. doi: 10.1165/ajrcmb.24.4.4008.
87. Bourgeois C, Rocha B, Tanchot C, A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002 297 2060 2063. doi: 10.1126/science.1072615.
88. Munroe ME, Bishop GA, A costimulatory function for T cell CD40. J Immunol 2007 178 671 682
89. Bullock TN, Yagita H, Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J Immunol 2005 174 710 717
90. Wang M, Li Y, Li W, Xia ZE, Wu Q, The CD40 gene polymorphism rs1883832 is associated with risk of acute coronary syndrome in a Chinese case-control study. DNA Cell Biol 2011 30 173 178. doi: 10.1089/dna.2010.1129.
91. Ma Y, Wang SX, Liu Y, Peng GG, Wang XM, Zhang B, Wu BH, Yu JM, Single nucleotide polymorphism of CD40 in the 5'-untranslated region is associated with ischemic stroke. Gene 2013 529 257 261. doi: 10.1016/j.gene.2013.07.086.
92. Zhou L, Xie L, Zheng D, Li N, Zhu J, Wang S, Li B, Ye L, Genetic variants of CD40 gene are associated with coronary artery disease and blood lipid levels. Biomed Res Int 2016 2016 1693619. doi: 10.1155/2016/1693619.
93. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA, Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999 5 1313 1316. doi: 10.1038/15271.
94. Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ, Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A 2000 97 7464 7469
95. Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P, Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998 394 200 203. doi: 10.1038/28204.
96. Schönbeck U, Sukhova GK, Shimizu K, Mach F, Libby P, Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A 2000 97 7458 7463
97. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA, CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998 391 591 594. doi: 10.1038/35393.
98. Lievens D, Zernecke A, Seijkens T, Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010 116 4317 4327. doi: 10.1182/blood-2010-01-261206.
99. Gerdes N, Seijkens T, Lievens D, Kuijpers MJ, Winkels H, Projahn D, Hartwig H, Beckers L, Megens RT, Boon L, Noelle RJ, Soehnlein O, Heemskerk JW, Weber C, Lutgens E, Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes. Arterioscler Thromb Vasc Biol 2016 36 482 490. doi: 10.1161/ATVBAHA.115.307074.
100. Bavendiek U, Zirlik A, LaClair S, MacFarlane L, Libby P, Schönbeck U, Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells. Arterioscler Thromb Vasc Biol 2005 25 1244 1249. doi: 10.1161/01.ATV.0000161420.55482.ef.
101. Smook ML, Heeringa P, Damoiseaux JG, Daemen MJ, de Winther MP, Gijbels MJ, Beckers L, Lutgens E, Tervaert JW, Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis 2005 183 275 282. doi: 10.1016/j.atherosclerosis.2005.03.051.
102. Zirlik A, Maier C, Gerdes N, CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007 115 1571 1580. doi: 10.1161/CIRCULATIONAHA.106.683201.
103. Lutgens E, Lievens D, Beckers L, Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010 207 391 404. doi: 10.1084/jem.20091293.
104. Getz GS, Reardon CA, Do the Apoe-/- and Ldlr-/- Mice Yield the Same Insight on Atherogenesis? Arterioscler Thromb Vasc Biol 2016 36 1734 1741. doi: 10.1161/ATVBAHA.116.306874.
105. von Scheidt M, Zhao Y, Kurt Z, Pan C, Zeng L, Yang X, Schunkert H, Lusis AJ, Applications and limitations of mouse models for understanding human atherosclerosis. Cell Metab 2017 25 248 261. doi: 10.1016/j.cmet.2016.11.001.
106. Borst J, Hendriks J, Xiao Y, CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005 17 275 281. doi: 10.1016/j.coi.2005.04.004.
107. Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA, Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009 229 216 231. doi: 10.1111/j.1600-065X.2009.00774.x.
108. Hendriks J, Xiao Y, Rossen JW, van der Sluijs KF, Sugamura K, Ishii N, Borst J, During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J Immunol 2005 175 1665 1676
109. Tesselaar K, Xiao Y, Arens R, van Schijndel GM, Schuurhuis DH, Mebius RE, Borst J, van Lier RA, Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol 2003 170 33 40
110. Coquet JM, Ribot JC, Bąbała N, Middendorp S, van der Horst G, Xiao Y, Neves JF, Fonseca-Pereira D, Jacobs H, Pennington DJ, Silva-Santos B, Borst J, Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway. J Exp Med 2013 210 715 728. doi: 10.1084/jem.20112061.
111. Laouar A, Haridas V, Vargas D, Zhinan X, Chaplin D, van Lier RA, Manjunath N, CD70+ antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa. Nat Immunol 2005 6 698 706. doi: 10.1038/ni1212.
112. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J, CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000 1 433 440. doi: 10.1038/80877.
113. Kobata T, Jacquot S, Kozlowski S, Agematsu K, Schlossman SF, Morimoto C, CD27-CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci U S A 1995 92 11249 11253
114. Xiao Y, Hendriks J, Langerak P, Jacobs H, Borst J, CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J Immunol 2004 172 7432 7441
115. Jacquot S, Kobata T, Iwata S, Morimoto C, Schlossman SF, CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. J Immunol 1997 159 2652 2657
116. Agematsu K, Kobata T, Yang FC, Nakazawa T, Fukushima K, Kitahara M, Mori T, Sugita K, Morimoto C, Komiyama A, CD27/CD70 interaction directly drives B cell IgG and IgM synthesis. Eur J Immunol 1995 25 2825 2829. doi: 10.1002/eji.1830251017.
117. Agematsu K, Nagumo H, Oguchi Y, Nakazawa T, Fukushima K, Yasui K, Ito S, Kobata T, Morimoto C, Komiyama A, Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood 1998 91 173 180
118. van Montfrans JM, Hoepelman AI, Otto S, van Gijn M, van de Corput L, de Weger RA, Monaco-Shawver L, Banerjee PP, Sanders EA, Jol-van der Zijde CM, Betts MR, Orange JS, Bloem AC, Tesselaar K, CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J Allergy Clin Immunol 2012 129 787 793.e6. doi: 10.1016/j.jaci.2011.11.013.
119. Salzer E, Daschkey S, Choo S, Gombert M, Santos-Valente E, Ginzel S, Schwendinger M, Haas OA, Fritsch G, Pickl WF, Förster-Waldl E, Borkhardt A, Boztug K, Bienemann K, Seidel MG, Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica 2013 98 473 478. doi: 10.3324/haematol.2012.068791.
120. Alkhairy OK, Perez-Becker R, Driessen GJ, Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency. J Allergy Clin Immunol 2015 136 703 712.e10. doi: 10.1016/j.jaci.2015.02.022.
121. Arens R, Nolte MA, Tesselaar K, Heemskerk B, Reedquist KA, van Lier RA, van Oers MH, Signaling through CD70 regulates B cell activation and IgG production. J Immunol 2004 173 3901 3908
122. Dang LV, Nilsson A, Ingelman-Sundberg H, Cagigi A, Gelinck LB, Titanji K, De Milito A, Grutzmeier S, Hedlund J, Kroon FP, Chiodi F, Soluble CD27 induces IgG production through activation of antigen-primed B cells. J Intern Med 2012 271 282 293. doi: 10.1111/j.1365-2796.2011.02444.x.
123. Hendriks J, Xiao Y, Borst J, CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med 2003 198 1369 1380. doi: 10.1084/jem.20030916.
124. van Oosterwijk MF, Juwana H, Arens R, Tesselaar K, van Oers MH, Eldering E, van Lier RA, CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development. Int Immunol 2007 19 713 718. doi: 10.1093/intimm/dxm033.
125. Peperzak V, Xiao Y, Veraar EA, Borst J, CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. J Clin Invest 2010 120 168 178. doi: 10.1172/JCI40178.
126. Dolfi DV, Boesteanu AC, Petrovas C, Xia D, Butz EA, Katsikis PD, Late signals from CD27 prevent Fas-dependent apoptosis of primary CD8+ T cells. J Immunol 2008 180 2912 2921
127. van Olffen RW, de Bruin AM, Vos M, Staniszewska AD, Hamann J, van Lier RA, de Vries CJ, Nolte MA, CD70-driven chronic immune activation is protective against atherosclerosis. J Innate Immun 2010 2 344 352. doi: 10.1159/000314772.
128. Arens R, Tesselaar K, Baars PA, van Schijndel GM, Hendriks J, Pals ST, Krimpenfort P, Borst J, van Oers MH, van Lier RA, Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 2001 15 801 812
129. Winkels H, Meiler S, Smeets E, CD70 limits atherosclerosis and promotes macrophage function. Thromb Haemost 2017 117 164 175. doi: 10.1160/TH16-04-0318.
130. Itani HA, Xiao L, Saleh MA, CD70 exacerbates blood pressure elevation and renal damage in response to repeated hypertensive stimuli. Circ Res 2016 118 1233 1243. doi: 10.1161/CIRCRESAHA.115.308111.
131. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S, Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002 3 135 142. doi: 10.1038/ni759.
132. Kanamaru F, Youngnak P, Hashiguchi M, Nishioka T, Takahashi T, Sakaguchi S, Ishikawa I, Azuma M, Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol 2004 172 7306 7314
133. Shevach EM, Stephens GL, The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol 2006 6 613 618. doi: 10.1038/nri1867.
134. Placke T, Kopp HG, Salih HR, Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. Clin Dev Immunol 2010 2010 239083. doi: 10.1155/2010/239083.
135. Gurney AL, Marsters SA, Huang RM, Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol 1999 9 215 218
136. Kwon B, Yu KY, Ni J, Yu GL, Jang IK, Kim YJ, Xing L, Liu D, Wang SX, Kwon BS, Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem 1999 274 6056 6061
137. Kim WJ, Bae EM, Kang YJ, Bae HU, Hong SH, Lee JY, Park JE, Kwon BS, Suk K, Lee WH, Glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR) mediates inflammatory activation of macrophages that can destabilize atherosclerotic plaques. Immunology 2006 119 421 429. doi: 10.1111/j.1365-2567.2006.02453.x.
138. Meiler S, Smeets E, Winkels H, Shami A, Pascutti MF, Nolte MA, Beckers L, Weber C, Gerdes N, Lutgens E, Constitutive GITR activation reduces atherosclerosis by promoting regulatory CD4+ T-cell responses-brief report. Arterioscler Thromb Vasc Biol 2016 36 1748 1752. doi: 10.1161/ATVBAHA.116.307354.
139. Clouthier DL, Watts TH, Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection. Cytokine Growth Factor Rev 2014 25 91 106. doi: 10.1016/j.cytogfr.2013.12.003.
140. Croft M, So T, Duan W, Soroosh P, The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009 229 173 191. doi: 10.1111/j.1600-065X.2009.00766.x.
141. Song J, So T, Cheng M, Tang X, Croft M, Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 2005 22 621 631. doi: 10.1016/j.immuni.2005.03.012.
142. Chen AI, McAdam AJ, Buhlmann JE, Scott S, Lupher ML Jr, Greenfield EA, Baum PR, Fanslow WC, Calderhead DM, Freeman GJ, Sharpe AH, Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 1999 11 689 698
143. Vu MD, Xiao X, Gao W, OX40 costimulation turns off Foxp3+ Tregs. Blood 2007 110 2501 2510
144. Stüber E, Strober W, The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 1996 183 979 989
145. Karulf M, Kelly A, Weinberg AD, Gold JA, OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis. J Immunol 2010 185 4856 4862. doi: 10.4049/jimmunol.1000404.
146. Wang X, Ria M, Kelmenson PM, Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 2005 37 365 372. doi: 10.1038/ng1524.
147. Olofsson PS, Söderström LA, Jern C, Sirsjö A, Ria M, Sundler E, de Faire U, Wiklund PG, Ohrvik J, Hedin U, Paulsson-Berne G, Hamsten A, Eriksson P, Hansson GK, Genetic variants of TNFSF4 and risk for carotid artery disease and stroke. J Mol Med (Berl) 2009 87 337 346. doi: 10.1007/s00109-008-0412-5.
148. Ria M, Eriksson P, Boquist S, Ericsson CG, Hamsten A, Lagercrantz J, Human genetic evidence that OX40 is implicated in myocardial infarction. Biochem Biophys Res Commun 2006 339 1001 1006. doi: 10.1016/j.bbrc.2005.11.092.
149. van Wanrooij EJ, van Puijvelde GH, de Vos P, Yagita H, van Berkel TJ, Kuiper J, Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007 27 204 210. doi: 10.1161/01.ATV.0000251007.07648.81.
150. Foks AC, van Puijvelde GH, Bot I, ter Borg MN, Habets KL, Johnson JL, Yagita H, van Berkel TJ, Kuiper J, Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis. J Immunol 2013 191 4573 4580. doi: 10.4049/jimmunol.1200708.
151. Kennedy MK, Willis CR, Armitage RJ, Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006 118 143 152. doi: 10.1111/j.1365-2567.2006.02354.x.
152. Lee SY, Lee SY, Kandala G, Liou ML, Liou HC, Choi Y, CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proc Natl Acad Sci U S A 1996 93 9699 9703
153. Gaspal FM, Kim MY, McConnell FM, Raykundalia C, Bekiaris V, Lane PJ, Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. J Immunol 2005 174 3891 3896
154. Shanebeck KD, Maliszewski CR, Kennedy MK, Picha KS, Smith CA, Goodwin RG, Grabstein KH, Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol 1995 25 2147 2153. doi: 10.1002/eji.1830250805.
155. Foks AC, Bot I, Frodermann V, de Jager SC, Ter Borg M, van Santbrink PJ, Yagita H, Kuiper J, van Puijvelde GH, Interference of the CD30-CD30L pathway reduces atherosclerosis development. Arterioscler Thromb Vasc Biol 2012 32 2862 2868. doi: 10.1161/ATVBAHA.112.300509.
156. Croft M, The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009 9 271 285. doi: 10.1038/nri2526.
157. Kwon BS, Hurtado JC, Lee ZH, Kwack KB, Seo SK, Choi BK, Koller BH, Wolisi G, Broxmeyer HE, Vinay DS, Immune responses in 4-1BB (CD137)-deficient mice. J Immunol 2002 168 5483 5490
158. Vinay DS, Choi BK, Bae JS, Kim WY, Gebhardt BM, Kwon BS, CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J Immunol 2004 173 4218 4229
159. Lee SW, Park Y, So T, Kwon BS, Cheroutre H, Mittler RS, Croft M, Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol 2008 9 917 926. doi: 10.1038/ni.1632.
160. Choi BK, Kim YH, Kwon PM, Lee SC, Kang SW, Kim MS, Lee MJ, Kwon BS, 4-1BB functions as a survival factor in dendritic cells. J Immunol 2009 182 4107 4115. doi: 10.4049/jimmunol.0800459.
161. Baessler T, Charton JE, Schmiedel BJ, Grünebach F, Krusch M, Wacker A, Rammensee HG, Salih HR, CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010 115 3058 3069. doi: 10.1182/blood-2009-06-227934.
162. Lee SW, Vella AT, Kwon BS, Croft M, Enhanced CD4 T cell responsiveness in the absence of 4-1BB. J Immunol 2005 174 6803 6808
163. Olofsson PS, Söderström LA, Wågsäter D, Sheikine Y, Ocaya P, Lang F, Rabu C, Chen L, Rudling M, Aukrust P, Hedin U, Paulsson-Berne G, Sirsjö A, Hansson GK, CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 2008 117 1292 1301. doi: 10.1161/CIRCULATIONAHA.107.699173.
164. Jeon HJ, Choi JH, Jung IH, CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation 2010 121 1124 1133. doi: 10.1161/CIRCULATIONAHA.109.882704.
165. Jung IH, Choi JH, Jin J, CD137-inducing factors from T cells and macrophages accelerate the destabilization of atherosclerotic plaques in hyperlipidemic mice. FASEB J 2014 28 4779 4791. doi: 10.1096/fj.14-253732.
166. Tu TH, Kim CS, Nam-Goong IS, Nam CW, Kim YI, Goto T, Kawada T, Park T, Yoon Park JH, Ryoo ZY, Park JW, Choi HS, Yu R, 4-1BBL signaling promotes cell proliferation through reprogramming of glucose metabolism in monocytes/macrophages. FEBS J 2015 282 1468 1480. doi: 10.1111/febs.13236.
167. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL, Ruben S, Murphy M, Eisenberg RJ, Cohen GH, Spear PG, Ware CF, LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998 8 21 30
168. Morel Y, Schiano de Colella JM, Harrop J, Deen KC, Holmes SD, Wattam TA, Khandekar SS, Truneh A, Sweet RW, Gastaut JA, Olive D, Costello RT, Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol 2000 165 4397 4404
169. Cai G, Freeman GJ, The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev 2009 229 244 258. doi: 10.1111/j.1600-065X.2009.00783.x.
170. Sandberg WJ, Halvorsen B, Yndestad A, Smith C, Otterdal K, Brosstad FR, Frøland SS, Olofsson PS, Damås JK, Gullestad L, Hansson GK, Oie E, Aukrust P, Inflammatory interaction between LIGHT and proteinase-activated receptor-2 in endothelial cells: potential role in atherogenesis. Circ Res 2009 104 60 68. doi: 10.1161/CIRCRESAHA.108.188078.
171. Lee WH, Kim SH, Lee Y, Lee BB, Kwon B, Song H, Kwon BS, Park JE, Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol 2001 21 2004 2010
172. Celik S, Langer H, Stellos K, May AE, Shankar V, Kurz K, Katus HA, Gawaz MP, Dengler TJ, Platelet-associated LIGHT (TNFSF14) mediates adhesion of platelets to human vascular endothelium. Thromb Haemost 2007 98 798 805
173. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C, RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001 103 1772 1777
174. Otterdal K, Smith C, Oie E, Pedersen TM, Yndestad A, Stang E, Endresen K, Solum NO, Aukrust P, Damås JK, Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. Blood 2006 108 928 935. doi: 10.1182/blood-2005-09-010629.
175. Lo JC, Wang Y, Tumanov AV, Bamji M, Yao Z, Reardon CA, Getz GS, Fu YX, Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 2007 316 285 288. doi: 10.1126/science.1137221.
176. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH, PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009 206 3015 3029. doi: 10.1084/jem.20090847.
177. Koga N, Suzuki J, Kosuge H, Haraguchi G, Onai Y, Futamatsu H, Maejima Y, Gotoh R, Saiki H, Tsushima F, Azuma M, Isobe M, Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts. Arterioscler Thromb Vasc Biol 2004 24 2057 2062. doi: 10.1161/01.ATV.0000145015.23656.e4.
178. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, Greenfield EA, Liang SC, Sharpe AH, Lichtman AH, Freeman GJ, Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 2003 33 3117 3126. doi: 10.1002/eji.200324270.
179. Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ, Keir ME, Freeman GJ, Sharpe AH, Lichtman AH, Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 2007 116 2062 2071. doi: 10.1161/CIRCULATIONAHA.107.709360.
180. Chen WJ, Hu XF, Yan M, Zhang WY, Mao XB, Shu YW, Human umbilical vein endothelial cells promote the inhibitory activation of CD4(+)CD25(+)Foxp3(+) regulatory T cells via PD-L1. Atherosclerosis 2016 244 108 112. doi: 10.1016/j.atherosclerosis.2015.11.002.
181. Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH, Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest 2007 117 2974 2982. doi: 10.1172/JCI31344.
182. Lee J, Zhuang Y, Wei X, Shang F, Wang J, Zhang Y, Liu X, Yang Y, Liu L, Zheng Q, Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J Mol Cell Cardiol 2009 46 169 176. doi: 10.1016/j.yjmcc.2008.10.028.
183. Bu DX, Tarrio M, Maganto-Garcia E, Stavrakis G, Tajima G, Lederer J, Jarolim P, Freeman GJ, Sharpe AH, Lichtman AH, Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol 2011 31 1100 1107. doi: 10.1161/ATVBAHA.111.224709.
184. Cochain C, Chaudhari SM, Koch M, Wiendl H, Eckstein HH, Zernecke A, Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. PLoS One 2014 9 e93280. doi: 10.1371/journal.pone.0093280.
185. Qiu MK, Wang SC, Dai YX, Wang SQ, Ou JM, Quan ZW, PD-1 and Tim-3 pathways regulate CD8+ T cells function in atherosclerosis. PLoS One 2015 10 e0128523. doi: 10.1371/journal.pone.0128523.
186. Hughes PE, Caenepeel S, Wu LC, Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol 2016 37 462 476. doi: 10.1016/j.it.2016.04.010.
187. Sakaguchi S, Yamaguchi T, Nomura T, Ono M, Regulatory T cells and immune tolerance. Cell 2008 133 775 787. doi: 10.1016/j.cell.2008.05.009.
188. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995 3 541 547
189. Ewing MM, Karper JC, Abdul S, de Jong RC, Peters HA, de Vries MR, Redeker A, Kuiper J, Toes RE, Arens R, Jukema JW, Quax PH, T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol 2013 168 1965 1974. doi: 10.1016/j.ijcard.2012.12.085.
190. Ma K, Lv S, Liu B, Liu Z, Luo Y, Kong W, Xu Q, Feng J, Wang X, CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE(-/-) mice. Cardiovasc Res 2013 97 349 359. doi: 10.1093/cvr/cvs330.
191. Matsumoto T, Sasaki N, Yamashita T, Emoto T, Kasahara K, Mizoguchi T, Hayashi T, Yodoi K, Kitano N, Saito T, Yamaguchi T, Hirata K, Overexpression of Cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2016 36 1141 1151. doi: 10.1161/ATVBAHA.115.306848.
192. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, BG9588 Lupus Nephritis Trial Group A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003 48 719 727. doi: 10.1002/art.10856.
193. André P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD, CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002 8 247 252. doi: 10.1038/nm0302-247.
194. Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, Drachman JG, Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma 2015 56 2569 2578. doi: 10.3109/10428194.2015.1007504.
195. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG, Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009 27 4371 4377. doi: 10.1200/JCO.2008.21.3017.
196. Fanale M, Assouline S, Kuruvilla J, Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol 2014 164 258 265. doi: 10.1111/bjh.12630.
197. Rosetti F, Mayadas TN, The many faces of Mac-1 in autoimmune disease. Immunol Rev 2016 269 175 193. doi: 10.1111/imr.12373.
198. Wolf D, Hohmann JD, Wiedemann A, Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis-but does not affect immunity and thrombosis in mice. Circ Res 2011 109 1269 1279. doi: 10.1161/CIRCRESAHA.111.247684.
199. Zarzycka B, Seijkens T, Nabuurs SB, Ritschel T, Grommes J, Soehnlein O, Schrijver R, van Tiel CM, Hackeng TM, Weber C, Giehler F, Kieser A, Lutgens E, Vriend G, Nicolaes GA, Discovery of small molecule CD40-TRAF6 inhibitors. J Chem Inf Model 2015 55 294 307. doi: 10.1021/ci500631e.
200. Chatzigeorgiou A, Seijkens T, Zarzycka B, Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proc Natl Acad Sci U S A 2014 111 2686 2691. doi: 10.1073/pnas.1400419111.
201. Diegmann J, Junker K, Gerstmayer B, Bosio A, Hindermann W, Rosenhahn J, von Eggeling F, Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. Eur J Cancer 2005 41 1794 1801. doi: 10.1016/j.ejca.2005.05.005.
202. Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, Schubert J, CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol 2005 173 2150 2153. doi: 10.1097/01.ju.0000158121.49085.ba.
203. Ryan MC, Kostner H, Gordon KA, Duniho S, Sutherland MK, Yu C, Kim KM, Nesterova A, Anderson M, McEarchern JA, Law CL, Smith LM, Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer 2010 103 676 684. doi: 10.1038/sj.bjc.6605816.
204. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H, Aguzzi A, Rammensee HG, Weller M, Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 2002 62 2592 2599
205. Trebing J, El-Mesery M, Schäfer V, Weisenberger D, Siegmund D, Silence K, Wajant H, CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants. Cell Death Dis 2014 5 e1035. doi: 10.1038/cddis.2013.555.
206. Yang ZZ, Grote DM, Xiu B, Ziesmer SC, Price-Troska TL, Hodge LS, Yates DM, Novak AJ, Ansell SM, TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia 2014 28 1872 1884. doi: 10.1038/leu.2014.84.
207. Grewal IS, CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets 2008 12 341 351. doi: 10.1517/14728222.12.3.341.
208. Registry of Clinical Trials ClinicalTrials Web site. https://clinicaltrials.gov/. Accessed October 22, 2016.
209. van de Ven K, Borst J, Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy 2015 7 655 667
210. Registry of Clinical Trials ClinicalTrials Web site. https://clinicaltrials.gov/. Accessed October 22, 2016.
211. He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, Marsh H, Keler T, Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol 2013 191 4174 4183. doi: 10.4049/jimmunol.1300409.
212. Boutros C, Tarhini A, Routier E, Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016 13 473 486. doi: 10.1038/nrclinonc.2016.58.
213. Larkin J, Chiarion-Sileni V, Gonzalez R, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015 373 23 34. doi: 10.1056/NEJMoa1504030.